Guanglei Yu

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair et al. · American Journal of Clinical Dermatology · 2023 · 147 citations · Full text

Medicine, Dermatology, Pharmacology +13

Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study

Brett King, Justin Ko, Seth Forman et al. · Journal of the American Academy of Dermatology · 2021 · 114 citations · Full text

Medicine, Dermatology, Pharmacology +13

The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring

Gaohong Dong, Lu Mao, Bo Huang et al. · Journal of Biopharmaceutical Statistics · 2020 · 76 citations · Full text

Public Health, Biostatistics, Cardiology +14

<scp>Long‐term</scp> efficacy and safety of baricitinib in patients with severe alopecia areata: <scp>104‐week</scp> results from <scp>BRAVE‐AA1</scp> and <scp>BRAVE‐AA2</scp>

Maryanne M. Senna, Arash Mostaghimi, Manabu Ohyama et al. · Journal of the European Academy of Dermatology and Venereology · 2024 · 45 citations · Full text

Medicine, Dermatology, Pharmacology +15

Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata

Brett King, Justin Ko, Ohsang Kwon et al. · JAMA Dermatology · 2024 · 43 citations · Full text

Medicine, Dermatology, Pharmacotherapy +11